Recombinant Human BTLA Fc Chimera (aa 31-153) Protein, CF

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

B- and T- lymphocyte attenuator (BTLA), also known as B- and T-lymphocyte-associated protein and CD272, is a type I transmembrane glycoprotein that belongs to the CD28 family of T cell co-stimulatory molecules (1-3). Mature human BTLA contains a 127 amino acid (aa) extracellular domain (ECD), a 21 aa transmembrane domain, and a 111 aa cytoplasmic domain. The ECD of human BTLA shares 42% and 44% aa identity with mouse and rat BTLA, respectively. Unlike other CD28 family members, the BTLA Ig domain in the ECD is of the I-type rather than V-type (4). BTLA is expressed on T cells, B cells, macrophages, dendritic cells and NK cells (5). BTLA is also unusual in its interaction with the TNF superfamily member HVEM rather than with B7 family ligands (6). Its expression is low in naïve T cells and increases during antigen-specific induction of anergy. BTLA apparently limits T cell numbers, since its deletion results in overproduction of T cells, especially CD8⁺ memory T cells that are hyper-responsive to TCR cross-linking (7). Under the control of ROR gamma t and IL-7, BTLA regulates the homeostasis and inflammatory responses of gamma δT cells (8). The binding of BTLA and HVEM does not preclude the concurrent binding of other HVEM ligands such as LIGHT or Lymphotoxin‑alpha (10).

Array 9509-BT

• BTLA/CD272 Antibodies
• BTLA/CD272 Lysates
• BTLA/CD272 Protein
• BTLA/CD272 Proteins and Enzymes
• BTLA/CD272 ELISA